Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]C Kristensen, P Kristjansen, H Hansen: Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 10, 1498–502 (1992)

  • [2]R Patchell, P Tibbs, J Walsh, R Dempsey, Y Maruyama, R Kryscio, W Markesbery, J Macdonald, B Young: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322, 494–500 (1990)

  • [3]P Sperduto, N Kased, D Roberge, Z Xu, R Shanley, X Luo, P Sneed, S Chao, R Weil, J Suh, A Bhatt, A Jensen, P Brown, H Shih, J Krikpatrick, L Gaspar, J Fiveash, V Chiang, J Knisely, C Sperduto, N Lin, M Mehta: Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30, 419–425 (2012)

  • [4]J Hubbs, J Boyd, D Hollis, J Chino, M Saynak, C Kelsey: Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer 116, 5038–5046 (2010)

  • [5]L Nayak, E Lee, P Wen: Epidemiology of brain metastases. Curr Oncol Rep 14, 48–54 (2012)

  • [6]R Patel, M Mehta: Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 13, 1675–1683 (2007)

  • [7]S Owen, L Souhami: The management of brain metastases in non-small cell lung cancer. Front Oncol 4, 248 (2014)

  • [8]F Lagerwaard, P Levendag, P Nowak, W Eijkenboom, P Hanssens, P Schmitz: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol 43, 795–803 (1999)

  • [9]E Weltman, J Salvajoli, R Brandt, R de Morais Hanriot, F Prisco, J Cruz, S de Oliveira Borges, D Wajsbrot: Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys 46, 1155–1161 (2000)

  • [10]J Lorenzoni, D Devriendt, N Massager, P David, S Ruíz, B Vanderlinden, P Van Houtte, J Brotchi, M Levivier: Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 60, 218–24 (2004)

  • [11]P Sneed, J Suh, S Goetsch, S Sanghavi, R Chappell, J Buatti, W Regine, E Weltman, V King, J Breneman, P Sperduto, M Mehta: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 53, 519–526 (2002)

  • [12]J Barnholtz-Sloan, C Yu, A Sloan, J Vengoechea, M Wang, J Dignam, M Vogelbaum, P Sperduto, M Mehta, M Machtay, M Kattan: A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 14, 910-918. (2012)

  • [13]D Rades, J Dunst, S Schild: A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 184, 251–255 (2008)

  • [14]J Cairncross, J Kim, J Posner: Radiation therapy for brain metastases. Ann Neurol 7, 529–541 (1980)

  • [15]C Vecht, H Haaxma-Reiche, E Noordijk, G Padberg, J Voormolen, F Hoekstra, J Tans, N Lambooij, J Metsaars, A Wattendorff: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33, 583–590 (1993)

  • [16]M Caffo, V Barresi, G Caruso, M Cutugno, G La Fata, M Venza, C Alafaci, F Tomasello: Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci 14, 2135–2174 (2013)

  • [17]E Gerstner, R Fine: Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25, 2306–2312 (2007)

  • [18]E Rivera, C Meyers, M Groves, V Valero, D Francis, B Arun, K Broglio, G Yin, G Hortobagyi, T Buchholz: Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107, 1348–1354 (2006)

  • [19]V Franciosi, G Cocconi, M Michiara, F Di Costanzo, V Fosser, M Tonato, P Carlini, C Boni, S Di Sarra: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85, 1599–1605 (1999)

  • [20]C Christodoulou, D Bafaloukos, H Linardou, G Aravantinos, A Bamias, M Carina, G Klouvas, D Skarlos, Hellenic Cooperative Oncology Group: Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 71, 61–65 (2005)

  • [21]D Ettinger, W Akerley, H Borghaei, A Chang, R Cheney, L Chirieac, T D’Amico, T Demmy, R Govindan, F Grannis Jr, S Grant, L Horn, T Jahan, R Komaki, F Kong, M Kris, L Krug, R Lackner, I Lennes, B Loo Jr, R Martins, G Otterson, J Patel, M Pinder-Schenck, K Pisters, K Reckamp, G Riely, E Rohren, T Shapiro, S Swanson, K Tauer, D Wood, S Yang, K Gregory, M Hughes, National comprehensive cancer network: Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 11, 645–653 (2013)

  • [22]N Rizvi, J Mazières, D Planchard, T Stinchcombe, G Dy, S Antonia, L Horn, H Lena, E Minenza, B Mennecier, G Otterson, L Campos, D Gandara, B Levy, S Nair, G Zalcman, J Wolf, P Souquet, E Baldini, F Cappuzzo, C Chouaid, A Dowlati, R Sanborn, A Lopez-Chavez, C Grohe, R Huber, C Harbison, C Baudelet, B Lestini, S Ramalingam: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16, 257–265 (2015)

  • [23]T Walbert, M Gilbert: The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 14, 299–306 (2009)

  • [24]W Ortuzar, N Hanna, E Pennella, G Peng, C Langer, M Monberg, G Scagliotti: Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer 13, 24–30 (2012)

  • [25]M Yamamoto, T Serizawa, T Shuto, A Akabane, Y Higuchi, J Kawagishi, K Yamanaka, Y Sato, H Jokura, S Yomo, O Nagano, H Kenai, A Moriki, S Suzuki, Y Kida, Y Iwai, M Hayashi, H Onishi, M Gondo, M Sato, T Akimitsu, K Kubo, Y Kikuchi, T Shibasaki, T Goto, M Takanashi, Y Mori, K Takakura, N Saeki, E Kunieda, H Aoyama, S Momoshima, K Tsuchiva: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15, 387–395 (2014)

  • [26]R Patchell, P Tibbs, W Regine, R Dempsey, M Mohiuddin, R Kryscio, W Markesbery, K Foon, B Young: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485–1489 (1998)

  • [27]C Jensen, M Chan, T McCoy, J Bourland, A deGuzman, T Ellis, K Ekstrand, K McMullen, M Munley, E Shaw, J Urbanic, S Tatter: Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg 114, 1585–1591 (2011)

  • [28]E McTyre, J Scott, P Chinnaiyan: Whole brain radiotherapy for brain metastasis. Surg Neurol Int 4(Suppl 4), S236–244 (2013)

  • [29]R Soffietti, M Kocher, U Abacioglu, S Villa, F Fauchon, B Baumert, L Fariselli, T Tzuk-Shina, R Kortmann, C Carrie, M Ben Hassel, M Kouri, E Valeinis, D van den Berge, R Mueller, G Tridello, L Collette, A Bottomley: A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life. J Clin Oncol 31, 65-72 (2013)

  • [30]D Greene-Schloesser, M Robbins: Radiation-induced cognitive impairment--from bench to bedside. Neuro Oncol 14 Suppl 4, iv37–44 (2012)

  • [31]A Attia, B Page, G Lesser, M Chan: Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol 15, 539–550 (2014)

  • [32]M Kocher, R Soffietti, U Abacioglu, S Villà, F Fauchon, B Baumert, L Fariselli, T Tzuk-Shina, R Kortmann, C Carrie, M Ben Hassel, M Kouri, E Valeinis, D van den Berge, S Collette, L Collette, R Mueller: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29, 134–141 (2011)

  • [33]E Chang, J Wefel, K Hess, P Allen, F Lang, D Kornguth, R Arbuckle, J Swint, A Shiu, M Maor, C Meyers: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10, 1037–1044 (2009)

  • [34]H Aoyam, H Shirato, M Tago, K Nakagawa, T Toyoda, K Hatano, M Kenjyo, N Oya, S Hirota, H Shioura, E Kunjeda, T Inomata, K Hayakawa, N Katoh, G Kobashi: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483–2491 (2006)

  • [35]S Lester, G Taksler, J Kuremsky, J Lucas, D Ayala-Peacock, D Randolph, J Bourland, A Laxton, S Tatter, M Chan: Clinical and economic outcomes of patients with brain metastases based on symptoms: an argument for routine brain screening of those treated with upfront radiosurgery. Cancer 120, 433–441 (2014)

  • [36]J Lucas, H Colmer, L White, N Fitzgerald, S Isom, J Bourland, A Laxton, S Tatter, M Chan: Competing Risk Analysis of Neurologic versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? Int J Radiat Oncol 92, 1008–1015 (2015)

  • [37]D Ayala-Peacock, A Peiffer, J Lucas, S Isom, J Kuremsky, J Urbanic, J Bourland, A Laxton, S Tatter, E Shaw, M Chan: A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro Oncol 16, 1283–1288 (2014)

  • [38]J Kuremsky, J Urbanic, W Petty, J Lovato, J Bourland, S Tatter, T Ellis, K McMullen, E Shaw, M Chan: Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery. Neurosurgery 73, 641–647 (2013)

  • [39]D Andrews, C Scott, P Sperduto, A Flanders, L Gaspar, M Schell, M Werner-Wasik, W Demas, J Ryu, J Bahary, L Souhami, M Rotman, M Mehta, W Curran: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665–1672 (2004)

  • [40]A Johnson, J Ruiz, R Hughes, B Page, S Isom, J Lucas, E McTyre, K Houseknecht, D Ayala-Peacook, D Bourland, W Hinson, A Laxton, S Tatter, W Devinski, K Watabe, M Chan: Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget Epub ahead of print, (2015)

  • [41]D Ayala-Peacock, A Attia, J Hepel, J Lucas, N Onyeuku, M Stavas, R Taylor, C Chung, J Fiveash, M Chan: A Multi-institutional Predictive Nomogram for Distant Brain Failure in Patients Treated with Upfront Stereotactic Radiosurgery Without Whole Brain Radiation Therapy. Int J Radiat Oncol • Biol • Phys 90, S126 (2014)

  • [42]M Roengvoraphoj, G Tsongalis, K Dragnev, J Rigas: Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev 39, 839–850 (2013)

  • [43]J Paez, P Jänne, J Lee, S Tracy, H Greulich, S Gabriel, P Herman, F Kaye, N Lindeman, T Boggon, K Naoki, H Sasaki, Y Fujii, M Eck, W Sellers, B Johnson, M Meyerson: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004)

  • [44]C Lee, C Brown, R Gralla, V Hirsh, S Thongprasert, C-M Tsai, E Tan, J Ho, T Chu da, A Zaatar, J Osorio Sanchez, V Vu, J Au, A Inoue, S Lee, V Gebski, J Yang: Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. JNCI J Natl Cancer Inst 105, 595–605 (2013)

  • [45]C Gridelli, M Bareschino, C Schettino, A Rossi, P Maione, F Ciardiello: Erlotinibin Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. Oncologist 12, 840–849 (2007)

  • [46]F Hirsch, M Varella-Garcia, J McCoy, H West, A Xavier, P Gumerlock, P Bunn, W Franklin, J Crowley, D Gandara: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A southwest oncology group study. J Clin Oncol 23, 6838–6845 (2005)

  • [47]M-S Tsao, A Sakurada, J-C Cutz, C-Q Zhu, S Kamel-Reid, J Squire, I Lorimer, T Zhang, N Liu, M Daneshmand, P Marrano, G da Cunha Santos, A Lagarde, R Richardson, L Seymour, M Whitehead, K Ding, J Pater, F Shepherd: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353, 133–144 (2005)

  • [48]D Luo, X Ye, Z Hu, K Peng, Y Song, X Yin, G Zhu, Q Ji, Y Peng: EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol 35, 2437–2444 (2014)

  • [49]G Ceresoli, F Cappuzzo, V Gregorc, S Bartolini, L Crinò, E Villa: Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15, 1042–1047 (2004)

  • [50]C Chiu, C Tsai, Y Chen, S Chiang, J Liou, R Perng: Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47, 129–138 (2005)

  • [51]A Eichler, K Kahle, D Wang, V Joshi, H Willers, J Engelman, T Lynch, L Sequist. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 12, 1193–1199 (2010)

  • [52]M Jamal-Hanjani, J Spicer: Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 18, 938–944 (2012)

  • [53]Y Togashi, K Masago, M Fukudo, Y Tsuchido, C Okuda, Y Kim, Y Ikemi, Y Sakamori, T.Mio, T Katsura, M Mishima: Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 68, 1089–1092 (2011)

  • [54]J Welsh, R Komaki, A Amini, M Munsell, W Unger, P Allen, J Chang, J Wefel, S McGovern, L Garland, S Chen, J Holt, Z Liao, P Brown, E Sulman, J Heymach, E Kim, B Stea: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31, 895–902 (2013)

  • [55]P Sperduto, M Wang, H Robins, M Schell, M Werner-Wasik, R Komaki, L Souhami, M Buyyounouski, D Khuntia, W Demas, S Shah, L Nedzi, G Perry, J Suh, M Mehta: A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85, 1312–1318 (2013)

  • [56]N Gerber, Y Yamada, A Rimner, W Shi, G Riely, K Beal, H Yu, T Chan, Z Zhang, A. Wu: Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys 89, 322–329 (2014)

  • [57]L Sequist, J Yang, N Yamamoto, K O’Byrne, V Hirsh, T Mok, S Geater, S Orlov, C Tsai, M Boyer, W Su, J Bennouna, T Kato, V Gorbunova, K Lee, R Shah, D Massey, V Zazulina, M Shahidi, M Schuler: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31, 3327–3334 (2013)

  • [58]N Katakami, S Atagi, K Goto, T Hida, T Horai, A Inoue, Y Ichinose, K Koboyashi, K Takeda, K Kiura, K Nishio, Y Seki, R Ebisawa, M Shahidi, N Yamamoto: LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31, 3335–3341 (2013)

  • [59]M Schuler: Efficacy of afatinib versus chemotherapy in treatment-naive patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease. Mini-Oral presentation at World Congress on Lung Cancer (2013)

  • [60]P Hoffknecht, A Tufman, T Wehler, T Pelzer, R Wiewrodt, M Schütz, M Serke, J Stohlmacher-Williams, A Marten, R Maria Huber, N Dickgreber: Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10, 156-163 (2015).

  • [61]L Sequist, J Soria, J Goldman, H Wakelee, S Gadgeel, A Varga, V Papadimitrakopoulou, B Solomon, G Oxnard, R Dziadziusko, D Aisner, R Doebele, C Galasso, E Garon, R Heist, J Logan, J Neal, M Mendenhall, S Nichols, Z Piotrowska, A Wozniak, M Raponi, C Karlovich, S Jaw-Tsai, J Isaacson, D Despain, S Matheny, L Rolfe, A Allen, D Camidge: Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 372, 1700–1709 (2015)

  • [62]P Jänne, J Yang, D Kim, D Planchard, Y Ohe, S Ramalingam, M Ahn, S Kim, W Su, L Horn, D Haggstrom, E Felip, J Kim, P Frewer, M Cantarini, K Brown, P Dickinson, S Ghiorghiu, M Ranson: AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. N Engl J Med 372, 1689–1699 (2015)

  • [63]E Kwak, Y Bang, D Camidge, A Shaw, B Solomon, R Maki, S Ou, B Dezube, P Janne, D Costa, M Varella-Garcia, W Kim, T Lynch, P Fidias, H Stubbs, J Engelman, L Sequist, W Tan, L Gandhi, M Mino-Kenudson, G Wei, S Shreeve, M Ratain, J Settleman, J Christensen, D Haber, K Wilner, R Salgia, G Shapiro, J Clark, A Iafrate: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363, 1693–1703 (2010)

  • [64]A Shaw, B Yeap, M Mino-Kenudson, S Digumarthy, D Costa, R Heist, B Solomon, H Stubbs, S Admane, U McDermott, J Settleman, S Kobayashi, E Mark, S Rodig, L Chirieac, E Kwak, T Lynch, A Iafrate: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27, 4247–4253 (2009)

  • [65]A Shaw, D Kim, K Nakagawa, T Seto, L Crinó, M Ahn, T De Pas, B Besse, B Solomon, F Blackhall, Y Wu, M Thomas, K O’Byrne, D Moro-Sibilot, D Camidge, T Mok, V Hirsh, G Riely, S Iyer, V Tassell, A Polli, K Wilner, P Janne: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368, 2385–2394 (2013)

  • [66]D Camidge, Y Bang, E Kwak, A Iafrate, M Varella-Garcia, S Fox, G Riely, B Solomon, S Ou, D Kim, R Salgia, P Fidias, J Engelman, L Gandhi, P Janne, D Costa, G Shapiro, P Lorusso, K Ruffner, P Stephenson, Y Tang, K Wilner, J Clark, A Shaw: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13, 1011–1019 (2012)

  • [67]J Gainor, S Ou, J Logan, L Borges, A Shaw: The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 8, 1570–1573 (2013)

  • [68]D Costa, A Shaw, S Ou, B Solomon, G Riely, M Ahn, C Zhou, S Shreeve, P Selaru, A Polli, P Schnell, K Wilner, R Wiltshire, D Camidge, L Crino: Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol 33, 1881–1888 (2015)

  • [69]D Costa, S Kobayashi, S Pandya, W Yeo, Z Shen, W Tan, K Wilner: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29, e443–5 (2011)

  • [70]Y Kim, H Ozasa, H Nagai, Y Sakamori, H Yoshida, Y Yagi, T Nakaoku, M Mishima: High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 8, e85–6 (2013)

  • [71]S Ou, P Jänne, C Bartlett, Y Tang, D Kim, G Otterson, L Crino, P Selaru, D Cohen, J Clark, G Riely: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25, 415–422 (2014)

  • [72]A Shaw, D Kim, R Mehra, D Tan, E Felip, L Chow, D Camidge, J Vansteenkiste, S Sharma, T De Pas, G Riely, B Solomon, J Wolf, M Thomas, M Schuler, G Liu, A Santoro, Y Lau, M Goldwasser, A Boral, J Engelman: Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer. N Engl J Med 370, 1189–1197 (2014)

  • [73]D Kim, R Mehra, D Tan, E Felip, L Chow, D Camidge, J Vansteenkiste, S Sharma, T De Pas, G Riely, B Solomon, J Wolf, M Thomas, M Schuler, G Liu, A Santoro, M Geraldes, A Boral, A Yovine, A Shaw: Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. J Clin Oncol 32, abstr 8003^ (2014)

  • [74]T Seto, K Kiura, M Nishio, K Nakagawa, M Maemondo, A Inoue, T Hida, N Yamamoto, H Yoshioka, M Harada, Y Ohe, N Nogami, K Takeuchi, T Shimada, T Tanaka, T Tamura: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14, 590–598 (2013)

  • [75]S Gadgeel, L Gandhi, G Riely, A Chiappori, H West, M Azada, P Morcos, R Lee, L FGarcia, L Yu, F Boisserie, L Di Laurenzio, S Golding, J Sato, S Yokoyama, T Tanaka, S Ou: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15, 1119–1128 (2014)

  • [76]T Johnson, P Richardson, S Bailey, A Brooun, B Burke, M Collins, J Cui, J Deal, Y Deng, D Dinh, L Engstrom, M He, J Hoffman, R Hoffman, Q Huang, R Kania, J Kath, H Lam, J Lam, P Le, L Lingardo, W Liu, M McTigue, C Palmer, N Sach, T Smeal, G Smith, A Stewart, S Timofeevski, H Zhu, J Zhu, H Zou, M Edwards: Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 57, 4720–4744 (2014)

  • [77]L Horn, J Infante, G Blumenschein, H Wakelee, H Arkenau, G Dukart, C Liang, K Harrow, J Gibbons, C Lovly, W Pao: A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. 2014 ASCO Annual Meeting o Title. J Clin Oncol 32, abstr 8030^ (2014)

  • [78]M Keir, M Butte, G Freeman, A Sharpe: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26, 677-704 2008

  • [79]T Gajewski, J Louahed, V Brichard: Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16, 399–403 (2010)

  • [80]M Ghiotto, L Gauthier, N Serriari, S Pastor, A Truneh, J Nunès, D Olive: PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol 22, 651–660 (2010)

  • [81]E Massarelli, V Papadimitrakopoulou, J Welsh, C Tang, A Tsao: Immunotherapy in lung cancer. Transl lung cancer Res 3, 53–63 (2014)

  • [82]S Yano, H Shinohara, R Herbst, H Kuniyasu, C Bucana, L Ellis, D Davis, D McConkey, I Fidler: Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60, 4959–4967 (2000)

  • [83]Y Kienast, L von Baumgarten, M Fuhrmann, W Klinkert, R Goldbrunner, J Herms, F Winkler: Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16, 116–122 (2010)

  • [84]M Socinski, C Langer, J Huang, M Kolb, P Compton, L Wang, W Akerley: Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27, 5255–5261 (2009)

  • [85]B Besse, S Lasserre, P Compton, J Huang, S Augustus, U Rohr: Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16, 269–278 (2010)

  • [86]B Besse, S Le Moulec, J Mazières, H Senellart, F Barlesi, C Chouaid, E Dansin, H Berard, L Falchero, R Gervais, G Robinet, A Ruppert, R Schott, H Lena, C Clement-Dchene, X Quantin, P Souquet, J Tredaniel, D Moro-Sibilot, M Perol, A Madroszyk, J Soria: Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin Cancer Res 21, 1896–1903 (2015)

  • [87]F Iwamoto, L Abrey, K Beal, P Gutin, M Rosenblum, V Reuter, L DeAngelis, A Lassman: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73, 1200–1206 (2009)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

Treatment of brain metastases of lung cancer in the era of precision medicine

Michael E. Haughton 1, Michael D. Chan 2, Kounosuke Watabe 3, Marcelo Bonomi 1, Waldemar Debinski 4, Glenn J. Lesser 1, Jimmy Ruiz 1,5,*
Affiliations
Article Info

1 Department of Medicine, Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA

2 Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA

3 W.G. (Bill) Hefner Veteran Administration Medical Center, Cancer Center, Salisbury, NC, USA

4 Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC, USA

5 Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA

*Author to whom correspondence should be addressed.

 

Abstract

Common and deadly complications of non-small cell lung cancer (NSCLC) are brain metastases (BM). BM portends a poorer prognosis with limited effective treatment options and current management strategies present several challenges from iatrogenic complications of supportive medications, optimal delivery of drug across the blood-brain barrier, and preservation of neurocognitive function. Long term side effects and survivorship issues have become more evident in the era of targeted therapy where a systemic disease is much better controlled. Targeted therapies and immunotherapy are beginning to provide improvements in responses and survival rates. With further advancements and experience, our knowledge in this era of precision medicine will likely lead to strides in improving the quality of life and overall survival of patients with BM from NSCLC. In this review, we present the most recent updates in treatment of BM in NSCLC in regards to targeted and immunotherapy.

Keywords

  • Brain Metastasis
  • Targeted Agents
  • Stereotactic Radiosurgery
  • Chemotherapy
  • Precision Medicine
  • Review

References